Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 5, 2022
Discovery & Translation

Intima’s public neoantigen discovery platform; plus MS autoantigens and more

BioCentury’s roundup of translational news
BioCentury | Feb 10, 2022
Discovery & Translation

Translational trendspotting: a Distillery dive into neurology

Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Nov 30, 2016
Distillery Therapeutics

Neurology

BioCentury | Mar 29, 2012
Distillery Therapeutics

Indication: Neurology

BioCentury | Dec 9, 2010
Distillery Therapeutics

Indication: Cancer

BioCentury | Sep 3, 2009
Targets & Mechanisms

Bv8: main pain player

BioCentury | Aug 20, 2009
Distillery Therapeutics

Indication: Neurology

BioCentury | May 11, 2009
Strategy

Latent Value Finds a Home

BioCentury | Apr 9, 2009
Distillery Therapeutics

This week in therapeutics

Items per page:
1 - 10 of 13
Help Center
Username
Request a Demo
Request Training
Ask a Question